Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.2.7.5 (
AOR
)
1,763
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The adipokine
resistin
is linked with obesity, inflammation and various cancers, including breast cancer. This study sought to determine whether certain polymorphisms in the gene encoding
resistin
,
RETN
, increase the risk of breast cancer susceptibility. We analyzed levels of
resistin
expression in breast cancer tissue and samples from The Cancer Genome Atlas database. We also examined associations between four
RETN
single nucleotide polymorphisms (SNPs; rs3745367, rs7408174, rs1862513 and rs3219175) and breast cancer susceptibility in 515 patients with breast cancer and 541 healthy women without cancer. Compared with wild-type (GG) carriers, those carrying the AG genotype of the
RETN
SNP rs3219175 and those carrying at least one A allele in the SNP rs3219175 had a higher chance of developing breast cancer (adjusted odds ratio,
AOR
: 1.295, 95% confidence intervals, CI: 1.065-1.575 and 2.202, 1.701-2.243, respectively). When clinical aspects and the
RETN
SNP rs7408174 were examined in the breast cancer cohort, the CT genotype was linked to late-stage disease, while women with luminal A disease and at least one C allele were likely to progress to stage III/IV disease and to develop highly pathological grade III disease. Moreover,
resistin
-positive individuals were at greater risk than
resistin
-negative individuals for developing pathological grade III disease (OR: 5.020; 95% CI: 1.380-18.259). This study details risk associations between
resistin
and
RETN
SNPs in breast cancer susceptibility in Chinese Han women.
...
PMID:Impacts of RETN genetic polymorphism on breast cancer development. 3222 95